CA2638040A1 - Treatment of metastatic breast cancer - Google Patents

Treatment of metastatic breast cancer Download PDF

Info

Publication number
CA2638040A1
CA2638040A1 CA002638040A CA2638040A CA2638040A1 CA 2638040 A1 CA2638040 A1 CA 2638040A1 CA 002638040 A CA002638040 A CA 002638040A CA 2638040 A CA2638040 A CA 2638040A CA 2638040 A1 CA2638040 A1 CA 2638040A1
Authority
CA
Canada
Prior art keywords
epcam
patients
dose
study
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002638040A
Other languages
English (en)
French (fr)
Inventor
Carsten Reinhardt
Robert Saller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2638040A1 publication Critical patent/CA2638040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA002638040A 2006-02-09 2007-02-09 Treatment of metastatic breast cancer Abandoned CA2638040A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77242106P 2006-02-09 2006-02-09
EP06002680 2006-02-09
US60/772,421 2006-02-09
EP06002680.4 2006-02-09
PCT/EP2007/001127 WO2007090670A1 (en) 2006-02-09 2007-02-09 Treatment of metastatic breast cancer

Publications (1)

Publication Number Publication Date
CA2638040A1 true CA2638040A1 (en) 2007-08-16

Family

ID=38110762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002638040A Abandoned CA2638040A1 (en) 2006-02-09 2007-02-09 Treatment of metastatic breast cancer

Country Status (9)

Country Link
US (3) US7976842B2 (https=)
EP (1) EP1981539B1 (https=)
JP (2) JP2009526770A (https=)
KR (1) KR101296264B1 (https=)
AU (1) AU2007213920B2 (https=)
CA (1) CA2638040A1 (https=)
IL (1) IL192944A0 (https=)
RU (1) RU2434640C2 (https=)
WO (1) WO2007090670A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
AU2007213920B2 (en) * 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
DE102006035617A1 (de) * 2006-07-31 2008-02-21 Siemens Ag Automatische Bestimmung von Tumorlast
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA026578B1 (ru) * 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
JP5130999B2 (ja) * 2008-03-31 2013-01-30 住友ベークライト株式会社 抗癌剤の有効性予測方法
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2011091154A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
FR2977674B1 (fr) * 2011-07-06 2015-08-14 Cisbio Bioassays Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US20130179184A1 (en) * 2012-01-06 2013-07-11 Katherine L. Hurst Individualized Dosing Technique With Multiple Variables
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015065505A1 (en) * 2013-10-29 2015-05-07 Duke University Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
US10975164B2 (en) 2018-02-26 2021-04-13 Emory University Antibodies useful for detection of human carcinoma antigen
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
RU2188025C2 (ru) * 2000-07-19 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака молочной железы
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
AU2007213920B2 (en) * 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
RU2769948C2 (ru) * 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью

Also Published As

Publication number Publication date
KR101296264B1 (ko) 2013-08-14
JP2009526770A (ja) 2009-07-23
RU2008130963A (ru) 2010-03-20
EP1981539A1 (en) 2008-10-22
IL192944A0 (en) 2009-02-11
WO2007090670A1 (en) 2007-08-16
US20090304716A1 (en) 2009-12-10
US8658172B2 (en) 2014-02-25
US20130177578A1 (en) 2013-07-11
US8337843B2 (en) 2012-12-25
EP1981539B1 (en) 2014-07-23
AU2007213920A1 (en) 2007-08-16
US20120009204A1 (en) 2012-01-12
KR20080091817A (ko) 2008-10-14
US7976842B2 (en) 2011-07-12
JP2013067645A (ja) 2013-04-18
RU2434640C2 (ru) 2011-11-27
AU2007213920B2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
US7976842B2 (en) Treatment of metastatic breast cancer
JP7116113B2 (ja) がんを治療するためのｐｄ－１／ｐｄ－ｌ１阻害剤
JP7482180B2 (ja) 癌のための併用療法
KR102502545B1 (ko) Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
JP6914336B2 (ja) 進行したｈｅｒ２発現がんの治療
US20180134803A1 (en) Treatment of her2-positive breast cancer
KR20200006538A (ko) 암 치료에서 화학요법제와 병용되는 항-fgfr2 항체
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
JP2022512866A (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
HK1123987B (en) Treatment of metastatic breast cancer
HK1123987A (en) Treatment of metastatic breast cancer
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
JP2026513770A (ja) 抗ｃｔｌａ４抗体を使用して黒色腫を治療する方法
TW202436335A (zh) 治療表現ｄｌｌ３的癌症之方法
TW202529802A (zh) 胃癌和／或胃食管結合部癌的治療
CN118900700A (zh) 用于治疗非小细胞肺癌的联合疗法
WO2023147673A1 (en) Combination therapy for use in treatment of non-small cell lung cancer
CN118974099A (zh) 实体瘤的治疗
KN026 et al. A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of KN026 in Combination with Chemotherapy in Subjects with HER2-positive Gastric Cancer (including Adenocarcinoma of Esophagogastric Junction) Who Have Failed First-line Treatment
CN101405029A (zh) 转移性乳腺癌的治疗

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20151027